Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020
22 Octobre 2020 - 1:00PM
Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage
company developing innovative gene therapies, today announced that
it will host a virtual R&D Day on Friday, October 30, 2020 at
11:30 AM Eastern time, to discuss the Company’s AXO-Lenti-PD gene
therapy for Parkinson’s disease.
Axovant’s Parkinson’s disease R&D Day will be moderated by
Chief R&D Officer, Gavin Corcoran,
M.D., and will feature presentations on the
current treatment landscape and unmet medical need for people
living with Parkinson’s disease from the following key opinion
leaders:
- Charles Adler, M.D., Ph.D., Professor at Mayo
Clinic College of Medicine in Arizona
- Jamie Eberling, Ph.D., Vice President of
Research Programs at the Michael J. Fox Foundation
- Stéphane Palfi, M.D., Ph.D., Professor of
Neurosurgery and Head of the Neurosurgery Department at Henri
Mondor Medical Center, Paris University (UPEC)
In addition, the Company will present data from the second
cohort of the Phase 2 SUNRISE-PD trial for AXO-Lenti-PD
including:
- Summary of available data from the second dose cohort at the
6-month timepoint following one-time dosing with AXO-Lenti-PD gene
therapy
- Individual patient-level data at 6-months after dosing:
○ Hauser diary “Good ON time” and “OFF time” changes
from baseline for all 4 patients
○ Levodopa-equivalent daily dose (LEDD) changes from baseline
for all 4 patients ○ UPDRS Part II and Part III
“OFF” scores for the 2 evaluable patients in the cohort
- 12-month evaluation for the first patient treated in Cohort 2,
who was assessed remotely
Drs. Adler, Palfi, and Eberling will be joined by Dr. Corcoran
to answer questions following the formal presentations.
AXO-Lenti-PD is the only investigational gene therapy for
Parkinson’s disease that delivers three genes via a lentiviral
vector to encode a set of critical enzymes required for endogenous
dopamine synthesis, with the goal of improving motor function and
restoring steady, tonic levels of dopamine in the brain. The gene
therapy aims to provide patient benefit for years following a
single administration.
To register for the R&D webcast, please click here.
A live audio webcast of the R&D Day can be accessed through
the Events & Presentations section of the company's website at
investors.axovant.com. An archived replay of the webcast will be
available on the company's website following the event.
Biographies of R&D Day
Panelists:
- Charles H. Adler, M.D., Ph.D. is currently
Consultant and Professor in the Department of Neurology at Mayo
Clinic College of Medicine in Arizona. He is also Co-Principal
Investigator at both Arizona Parkinson's Disease Consortium and
Arizona Study of Aging and Neurodegenerative Disorders in
Scottsdale, Arizona. Dr. Adler received his Ph.D. in pharmacology
and his medical degree, from the New York University School of
Medicine. He did his neurology residency at the University of
Pennsylvania and a fellowship in movement disorders at Graduate
Hospital/University of Pennsylvania in Philadelphia. He then joined
the staff at Mayo Clinic in Scottsdale, Arizona.Dr. Adler has
received numerous grants to investigate experimental treatments for
Parkinson's disease, essential tremor, dystonia, restless legs
syndrome, and chronic traumatic encephalopathy (CTE). He serves as
an advisory member to many different international medical
societies such as the International Parkinson and Movement Disorder
Society, MDS Industry Education and Services Committee, and the
American Academy of Neurology Section of Movement Disorders. Dr.
Adler has a commitment to education having trained residents, 14
fellows and graduate students, and has given many invited lectures.
Dr. Adler’s main research interests are investigating tissue
diagnostic tests for Parkinson’s disease, biomarkers for an early
diagnosis of Parkinson’s disease and PD with dementia, and
identification of new treatments for PD and PD with dementia. He
also has been investigating essential tremor, restless legs
syndrome, and dystonia. He has published over 400 research papers
and reviews, and edited a book entitled Parkinson's Disease and
Movement Disorders: Diagnosis and Treatment Guidelines for the
Practicing Physician. In 2006, Dr. Adler was awarded the Mayo
Clinic Distinguished Investigator of the Year Award.
- Stéphane Palfi, M.D., Ph.D. is a Professor of
Neurosurgery and Head of the Neurosurgery Department at Henri
Mondor Medical Center, Paris University (UPEC). His interests are
in developmental therapeutics for Parkinson’s disease, Huntington’s
disease, tremor, dystonia, and psychiatric disorders. He has worked
extensively in the area of electrical neuromodulation of the brain
in movement disorders, gene therapy for Parkinson’s disease, cell
grafting for Huntington’s and Parkinson’s disease as well as
primate models of neurodegenerative disorders.Dr. Palfi has
published extensively on trophic factor- and enzyme-based gene
therapy in Parkinson’s disease and Huntington’s disease. He is a
principal investigator on numerous preclinical and clinical studies
and has been involved in studies of many novel agents including
implanted brain devices, optogenetic, homeoprotein, trophic factors
GDNF, CNTF and dopamine lentiviral vectors.
- Jamie Eberling, Ph.D. joined the Michael J.
Fox Foundation (MJFF) in 2009. As Vice President, Research
Programs, Dr. Eberling stays closely linked to the Parkinson’s
research community in order to develop an aggressive and innovative
agenda for accelerating research and drug development for
Parkinson’s disease. This ensures that MJFF research priorities
reflect and best serve the ultimate needs of patients. Dr. Eberling
regularly meets with academic and industry researchers around the
world to identify promising proposals to support, providing
troubleshooting and ongoing management of projects as they go
forward. She also supports the Foundation’s priority interests in
translating promising new therapies into the clinic. Jamie’s
primary responsibilities are managing the PET imaging program,
including alpha-synuclein tracer development, the non-motor
symptomatic program aimed at developing new therapies for non-motor
symptoms, and the clinical trials that are funded by MJFF.Dr.
Eberling earned undergraduate and graduate degrees in biological
psychology from the University of California at Berkeley, later
moving to the Lawrence Berkeley National Laboratory where she
developed expertise in neuroimaging techniques and gene therapy
approaches for Parkinson’s disease.
- Gavin Corcoran, M.D. joined Axovant as Chief
R&D Officer. In his career, he has overseen successful drug
development across multiple therapeutic areas, including neurology
and psychiatry, and was previously Chief Medical Officer of
Allergan plc and Actavis. Dr. Corcoran was Executive Vice President
for Global Medicines Development at Forest Laboratories prior to
the acquisition of Forest Laboratories by Actavis. Dr. Corcoran
also served as Head of Late Stage Clinical Development for
Inflammation and Immunology at Celgene, and as Chief Scientific
Officer and head of R&D at Stiefel Laboratories. Earlier in his
career he held leadership roles in clinical development and
regulatory affairs at Amgen, Schering-Plough, and Bayer. He
received his MB BCh from the University of the Witwatersrand in
South Africa and completed his clinical training in internal
medicine and infectious diseases at the University of Texas Health
Science Center at San Antonio.
About Axovant Gene Therapies
Axovant Gene Therapies is a clinical-stage gene
therapy company focused on developing a pipeline of innovative
product candidates for debilitating neurodegenerative diseases. Our
current pipeline of gene therapy candidates target GM1
gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease
and Sandhoff disease), and Parkinson’s disease. Axovant is focused
on accelerating product candidates into and through clinical trials
with a team of experts in gene therapy development and through
external partnerships with leading gene therapy organizations. For
more information, visit www.axovant.com.
Contacts:
Investors
Parag MeswaniAxovant Gene Therapies Ltd.(212)
547-2523investors@axovant.com
Media
Josephine Belluardo, Ph.D. LifeSci
Communications(646)
751-4361jo@lifescicomms.commedia@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024